NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Genevant Sciences

Genevant Sciences

Private
Vancouver, British ColumbiaHealthcare & Life Scienceshttps://www.genevant.com/

Last Round

Corporate Funding

Jul 31, 2020

Est. Valuation

$87.5M

Total Funding Raised

$40M

Company Overview

Genevant Sciences is a biotechnology company that provides nucleic acid delivery technology, including lipid nanoparticle (LNP) platforms, for the development of RNA-based therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

lipid nanoparticle deliveryLNP technologynucleic acid deliveryRNA deliverytechnology licensingdrug delivery platformmRNA deliverypicks and shovels biotechsiRNA deliverygene editing deliveryintellectual property licensingRNA therapeuticsligand conjugate deliverypharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genevant Sciences Comparables

Compare Genevant Sciences with similar companies based on industry and business-model similarity.

Genevant Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Acuitas Therapeutics
92%
NanoVation Therapeutics
88%
Lemonex Inc.
77%

Genevant Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingJul 31, 2020
SeedApr 11, 2018

Key People

Founding team and executive leadership

James Heyes

Chief Executive Officer

Executive Team

Ed Yaworski

Chief Technology Officer, Vice President, Pharmaceutical Development

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 27, 2024

    Monthly visitors increased 555% MoM, reaching 7.2K.

  • Aug 13, 2023

    Grew 18% QoQ from 40 to 47 employees.

Genevant Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Genevant Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Genevant Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersVancouver, British Columbia
Employee Range56
Year Founded2018
Last FundingJul 31, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.